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Objectives: To evaluate the relationship between polypharmacy and ART, delivered as conventional multi-tablet
three-drug regimens, single-tablet regimens or less-drug regimens (simplified mono or dual regimens).
Methods: We conducted a cross-sectional analysis of electronic data from the prospective Modena HIV Metabolic
Clinic Cohort Study. We included the last clinical observation for each patient from January 2006 to December
2015. Polypharmacy was defined as the use of five or more medications (excluding ART). Multi-morbidity was
classified as the presence of two or more non-infectious comorbidities. Factors associated with different ARTregi-
mens were analysed using multivariable multinomial logistic regression analyses with multi-tablet three-drug
regimens as the reference.
Results: A total of 2944 patients (33.7% females) were included in the analysis. Multinomial logistic regression
analysis identified polypharmacy to be negatively associated with single-tablet regimens [relative risk reduction
(RRR)¼0.48, 95% CI¼0.28–0.81] independently from frailty (RRR¼0.68, 95% CI¼0.59–0.78), after correction
for age, gender, HIV infection duration, current and nadir CD4 and calendar year. This association was not found
comparing multi-tablet three-drug regimens and less-drug regimens.
Conclusions: Single-tablet regimens are less likely to be prescribed in patients with polypharmacy. Single-tablet
regimens are perceived to be less flexible in patients with multi-morbidity and at higher risk of drug–drug
interaction.
Introduction
The prolonged survival of HIV-infected individuals on combination
ART has been accompanied by a marked rise in prevalence of con-
comitant diseases usually associated with ageing.1 In the Modena
HIV Metabolic Clinic (MHMC), 65% of individuals receiving ART are
in their fifties.2 The ATHENA investigators estimated that up to
60% of the patients with HIV will have multi-morbidity (MM) by
2030.3 The major consequence of MM is a corresponding rise in
the number of prescribed medications for each individual, also
known as polypharmacy (PP).4,5 Whilst PP is not an inevitable con-
sequence of MM, the two are closely linked, and it is difficult to dis-
sect their individual contributions to mortality, disability,
functional decline, poor quality of life and high healthcare
costs.6 This is particularly true for ART, which is associated with
a high risk for drug–drug interactions and toxicities, which overlap
with diseases of ageing such as renal impairment, metabolic syn-
drome and type II diabetes, bone disease and hyperlipidaemia.
The concept of frailty may be useful in discriminating whether
it is the morbidities themselves or the toxicity of prescribed treat-
ments that contribute more to adverse outcomes.
Frailty reflects a multi-system failure in a vulnerable person
with impaired responses to various external stressors.7 In clinical
practice, frailty can be operationalized as an ‘index’, which counts
the number of deficits individuals have accumulated out of vari-
ous health measures and presents them as a proportion.8,9 In
contrast to the phenotypic approach, any measure can be
included in a frailty index (FI) if it is generally related to age and
poor health, and if the group of items covers multiple physio-
logical systems. When at least 30 items are included, the propor-
tion of deficits accumulated appears more informative than the
specific nature of those deficits.
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The FI was able to predict future incidence of MM in a large HIV
cohort.10
Optimization of ART strategy in patients with MM who are
already taking multiple drugs can be challenging, requiring ART
regimens to be tailored to minimize pill burden, risk of toxicity
and drug–drug interactions. New strategies have been developed
alongside conventional triple combination ART administered as
multi-tablet regimens (MTR). They include use of co-formulated,
fixed-dose single-tablet regimens (STR) administered once daily,
as well as less-drug regimens (LDR), which reduce the number
of compounds administered to either monotherapy or dual com-
bination therapy.11
In this study, we sought to evaluate the relationship between
MM, frailty, PP and ART strategy in patients with HIV.
Methods
Setting and sample
This is a cross-sectional analysis of data from the prospective MHMC
cohort, whose electronic data collection was initiated in 2003 –04 to
assess comprehensively the longitudinal metabolic changes among peo-
ple with HIV.2,12
We included last patient visits from 2006 to 2015 to have a decade of
observation from the start of contemporary ART regimens. The data
included in the cohort study are those used in the clinical care of partici-
pants, including disease diagnoses and vital statistics.




A complete drug history was collected by physicians at each patient visit
and recorded using the Anatomical Therapeutic Chemical classification
system, that divides active substances into different groups according to
the organ or system on which they act and their therapeutic, pharmaco-
logical and chemical properties.13
PP was defined as the use of five or more medications identified with
the fourth level of the Anatomical Therapeutic Chemical classification sys-
tem (chemical/pharmacological/therapeutic subgroups) at chronic use,
excluding ART.13
To distinguish acute exposure to a drug from chronic use of medication
the latter was classified as the consecutive prescription of at least
4 months of medication with the same drug in the study year.
Antiretroviral strategies were categorized into the following three
groups: (i) MTR (triple combination ART administered in two or more pills
a day); (ii) STR (co-formulated, fixed-dose triple combination administered
once daily); and (iii) LDR (less than three ART compounds administered as
either monotherapy or dual combination therapy).
Demographic and clinical data
Demographic and clinical data were collected from electronic patient
charts.
HIV-related variables included: current and nadir CD4 T cell counts (cate-
gorized into clinically relevant groups as follows: .500, 351–500, 101–350
and ≤100), current HIV-RNA detectability and present and cumulative
exposure to ART classes, year of initiation of current ART categorized into
three time periods (2006–08, 2009–12 and 2013–15).
MM was classified as the presence of two or more of non-infectious
comorbidities, including cardiovascular disease, end-stage kidney disease,
cancer, osteoporosis, hypertension, type 2 diabetes mellitus, liver cirrhosis
and chronic obstructive pulmonary disease.
Frailty
An FI was calculated based on the deficit accumulation approach,9 previ-
ously applied in the same cohort.10
Health variables included in the frailty indices and description of deficit
scoring are listed in Table S1 (available as Supplementary data at JAC Online).
We assessed the effect of frailty independently from HIV-related vari-
ables and non-infectious comorbidities, excluding these variables as items
in the index.10
Statistical analyses
The cohort was divided into three ART strategy groups: MTR, STR and LDR.
Normally distributed continuous variables were compared among the
three groups using ANOVA, while Kruskal–Wallis test was used for non-
normally distributed variables. Differences of categorical variables were
analysed using the x2 test.
Factors associated with different ART regimens were analysed using
multivariable multinomial logistic regression analyses with MTR as the
reference.
To avoid co-linearity between age and duration of HIV infection, a
residual analysis was conducted between these two variables after uni-
variate linear regression. Residuals of HIV duration were included in the
multivariable multinomial regression analysis.
Statistical significance level was set for P,0.05. All statistical analyses
have been conducted with STATA 13.1 for Mac (StataCorp Ltd, College
Station, TX, USA).
Results
A total of 2944 patients (33.7% females) were considered for the
analysis.
The median duration of HIV infection was 19 years (IQR¼12.5–
23.7), the median CD4 cell count was 638 (IQR¼460–830) with a
nadir of 192 (IQR¼80–290), and 2853 patients had an undetect-
able HIV viral load (96.9%). The mean age of the entire cohort
was 48.6 (SD¼8.2).
Table 1 describes demographic and anthropometric variables
of patients included in the analysis, divided per ARTstrategy group.
Within the STR group, 350 patients were on efavirenz/emtrici-
tabine/tenofovir, 100 on rilpivirine/emtricitabine/tenofovir and 14
on elvitegravir/cobicistat/emtricitabine/tenofovir.
We analysed the interrelationship between the study covari-
ates, namely MM, PP and FI, which were highly co-linear. The
MM and PP result correlated with Pearson’s r coefficient (0.40,
P,0.001). Similar results were found for the analysis of FI and
PP (r¼0.18, P,0.001). The capacity to discriminate MM and PP
is depicted by the lower number of patients with MM with no PP
(n¼172, 5.84%), versus the higher number of patients with FI
above the median and no PP (n¼1523, 51.7%).
A significant association was found between ARTregimens and
both FI (STR b¼20.62, P,0.001; LDR b¼20.11, P¼0.049; with
MTR as the reference) and PP (STR versus MTR OR¼0.45,
P¼0.001; LDR versus MTR OR¼1.62, P¼0.001).
To explore their independent contribution to ART strategy we
built two different multinomial logistic regression analysis com-
paring LDR with MTR and STR with MTR (Figure 1). Factors asso-
ciated with STR were male gender, younger age, lower HIV
duration, year of ART initiation and lower FI; the PP result was
negatively associated with STR. The LDR strategy was associated
with older age, longer HIV duration and year of ART initiation; FI
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Discussion
We observed a striking independent association between PP and FI,
and a lower likelihood of using an STR. This is despite the increasing
median age of our cohort (data not shown) with a corresponding
increase in MM, and an increasing tendency to use STR with calendar
year. Whilst this might run counter to the notion that the simplicity
offered by STR helps to reduce the pill burden in individuals already
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Multinomial logistic regression: STR(a) (b)
Figure 1. Multinomial logistic regression analysis (more likely, less likely). RRR, relative risk reduction.
Table 1. Demographic and anthropometric variables of the patients included in the analysis, according to ART strategy group
MTR (n¼2025) STR (n¼464) LDR (n¼455) P
Women, n (%) 737 (36.40) 110 (23.71) 145 (31.87) ,0.001
Age (years), mean (SD) 48.37 (8.03) 47.22 (8.01) 52.13 (7.75) ,0.001
Current smokers, n (%) 493 (45.52) 60 (36.81) 76 (35.51) 0.006
Sedentary life, n (%) 646 (59.54) 65 (39.88) 91 (42.72) ,0.001
No alcohol, n (%) 663 (61.16) 92 (56.79) 134 (62.91) 0.466
,20 g/day of alcohol, n (%) 410 (37.82) 69 (42.59) 75 (35.21)
.20 g/day of alcohol, n (%) 11 (1.01) 1 (0.62) 4 (1.88)
Waist circumference (cm), mean (SD) 86.91 (10.16) 87.46 (9.03) 89.55 (12.03) 0.003
BMI (kg/m2), mean (SD) 23.54 (3.80) 23.72 (3.27) 24.21 (4.26) 0.064
Fasting glucose (mg/dL), mean (SD) 97.23 (23.20) 98.20 (16.59) 99.48 (29.78) 0.177
HOMA-IR, median (IQR) 2.64 (1.56–4.31) 1.98 (1.25–3.43) 2.26 (1.52–3.60) ,0.001
Triglycerides (mg/dL), mean (SD) 165.29 (120.39) 132.59 (89.38) 182.00 (138.64) ,0.001
Total cholesterol (mg/dL), mean (SD) 189.72 (61.51) 185.51 (37.33) 199.27 (50.60) 0.001
HDL cholesterol (mg/dL), mean (SD) 49.75 (16.88) 50.25 (14.97) 50.77 (17.57) 0.482
LDL cholesterol (mg/dL), mean (SD) 114.77 (35.76) 114.30 (30.67) 121.15 (37.74) 0.002
Metabolic syndrome, n (%) 229 (11.31) 37 (7.97) 71 (15.60) ,0.001
CD4 nadir (/mL), median (IQR) 183 (78–280) 222 (114–330) 180 (73.5–269) ,0.001
Current CD4 (/mL), median (IQR) 625 (439–821) 680 (515–854) 663 (484–838) 0.002
Cumulative exposure to ARV (months), median (IQR) 127 (74–185) 112 (62–173) 143 (94–193) ,0.001
Cumulative exposure to NRTIs (months), median (IQR) 127 (74–184) 112 (62–173) 134 (70–186) 0.004
Cumulative exposure to NNRTIs (months), median (IQR) 18 (0–65) 73 (36–120) 28.5 (1–66) ,0.001
Cumulative exposure to PIs (months), median (IQR) 58 (21–101) 0 (0–39) 104.5 (56–154) ,0.001
FI (months), median (IQR) 0.32 (0.25–0.41) 0.26 (0.19–0.33) 0.31 (0.25–0.38) ,0.001
PP, n (%) 207 (10.22) 23 (4.96) 71 (15.60) ,0.001
MM, n (%) 205 (10.12) 29 (6.25) 79 (17.36) ,0.001
ARV, antiretrovirals.
With the exceptions of female sex and PP, percentages are calculated with respect to the number of available data, not with respect to the overall data.
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taking many tablets, the findings are not necessarily unexpected.
Most of the STR available during the period of our study contained
tenofovir with or without cobicistat, or else abacavir. Prescribers
may have chosen to avoid these drugs in a population at greater
risk of bone, renal and cardiovascular adverse events as well as
restricted ability to avoid or manage drug interactions. In patients
with MM, the MTR and LDR regimens offer greater flexibility to tailor
ART around existing co-medications. The introduction of STR where
tenofovir disoproxil fumarate has been substituted with a newer for-
mulation, tenofovir alafenamide may provide some added flexibility
to tenofovir-containing STR.
The high rates of MM, frailty and PP observed in our cohort is
representative of large cohorts in the industrialized world. The
MHMC, like other providers of outpatient HIV care in Italy, offers
direct free of charge access to clinics and medications.2
Although the MHMC is a tertiary referral centre, most patients
attend from the local catchment population and are represen-
tative of the general HIV outpatient setting in Italy. We
observed that female patients (mean age was 47.1, SD 7.5)
were less likely to receive STR, possibly because of a previous
reluctance to use efavirenz in women planning to conceive,
and concerns over tenofovir use in postmenopausal osteopor-
osis. Conversely, older age was associated with higher use of
LDR. This may have been driven by the need to reduce ART toxi-
cities in an age category where MM is highly prevalent. Smoking
was highly prevalent in all patient groups. Individuals with a
metabolic syndrome phenotype, as characterized by waist cir-
cumference, homeostasis model assessment of insulin resist-
ance (HOMA-IR) and presence of lipodystrophy, were more
likely to receive an LDR as metabolic friendly drug associations
were needed here.
A novel aspect of our study was to utilize the FI as a means of
discriminating between MM and PP. Frailty is a measure of clinical
complexity and the clinical burden of MM, discriminating vulner-
able patients with and without PP. This allowed us to utilize
these two clinical variables in the same prediction model and dis-
sect the association between PP and ART strategy.
Knowledge of ART strategies utilized in different groups of
individuals receiving ART provides a greater understanding of
unmet needs, particularly for older, multi-morbid and frail
patients where optimized ART is still not available in a single,
fixed-dose formulation. Current treatment guidelines generally
fail to reflect this, and continued emphasis on the use of
STR to improve adherence needs to be balanced against the
limitations of currently available STR for complex individuals
with MM.14
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